Table 2. MET screening results and gene status based on MET/CEN-7 ratio (N=1,580).
| Amplified (MET/CEN-7 ≥2.0), n (%) | Non-amplified (MET/CEN-7 <2.0 and MET/CEN-7 ≥0.8), n (%) | Deletion (MET/CEN-7 <0.8), n (%) | Total, n (%) | |
|---|---|---|---|---|
| All | 113 (7.2) | 1,329 (84.1) | 138 (8.7) | 1,580 (100.0) |
| Regions | ||||
| Asia | 26 (9.4) | 242 (87.4) | 9 (3.2) | 277 (100.0) |
| Europe/Australia | 75 (6.6) | 953 (83.4) | 114 (10.0) | 1,142 (100.0) |
| North America | 11 (7.1) | 128 (83.2) | 15 (9.7) | 154 (100.0) |
| South America | 1 (14.3) | 6 (85.7) | 0 (0.0) | 7 (100.0) |
| Age, years | ||||
| Mean (SD) | 59.1 (13.0) | 60.0 (12.0) | 64.0 (11.6) | 60.3 (12.1) |
| Median (range) | 59.0 (25–85) | 62.0 (19–87) | 65.0 (26–96) | 62.0 (19–96) |
| Sex | ||||
| Male | 76 (6.7) | 942 (83.2) | 114 (10.1) | 1,132 (100.0) |
| Female | 37 (8.3) | 387 (86.4) | 24 (5.3) | 448 (100.0) |
| Tumor site | ||||
| Gastric | 70 (7.1) | 855 (87.2) | 56 (5.7) | 981 (100.0) |
| GEJ | 11 (6.5) | 137 (81.1) | 21 (12.4) | 169 (100.0) |
| Esophageal | 14 (6.0) | 178 (76.4) | 41 (17.6) | 233 (100.0) |
| Metastatic | 18 (9.1) | 160 (80.8) | 20 (10.1) | 198 (100.0) |
| MET/CEN-7 ratio | ||||
| Mean (SD) | 7.1 (5.7) | 1.1 (0.2) | 0.7 (0.1) | |
| Median (range) | 5.5 (2.0–39.2) | 1.1 (0.8–<2.0) | 0.7 (0.5–<0.8) |
MET, mesenchymal epithelial transition factor gene. CEN-7, centromere of chromosome 7; GEJ, gastroesophageal junction.